Trial Profile
Phase II Study of Pembrolizumab and Nab-paclitaxel in HER-2 Negative Metastatic Breast Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 08 Mar 2024
Price :
$35
*
At a glance
- Drugs Paclitaxel (Primary) ; Pembrolizumab (Primary)
- Indications Adenocarcinoma; Advanced breast cancer; HER2 negative breast cancer; HER2 positive breast cancer; Triple negative breast cancer
- Focus Therapeutic Use
- 13 Nov 2023 Protocol of this study has been amended as this study is no longer a observational, cohort study, Number of treatment arms has been changed to 3 from 2.
- 05 Aug 2022 Status changed from recruiting to active, no longer recruiting.
- 05 Aug 2022 Planned End Date changed from 1 Dec 2021 to 1 Dec 2024.